Mechanism of action of bone morphogenetic protein 9 in portopulmonary hypertension
10.3969/j.issn.1001-5256.2022.03.037
- VernacularTitle:骨形态发生蛋白9在门静脉性肺动脉高压中的作用机制
- Author:
Ruihua ZHANG
1
;
Tingting QIN
1
;
Yueming SHAO
2
;
Yu ZHANG
3
;
Xiaoyu WEN
1
Author Information
1. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China
2. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China;Department of Infection and Immunity, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai 201508, China
3. Department of Hepatology, The First Hospital of Jilin University, Changchun 130021, China;Department of Pediatric Endocrinology, Genetics, and Metabolism, The First Hospital of Jilin University, Changchun 130021, China
- Publication Type:Reviews
- Keywords:
Hypertension, Pulmonary;
Bone Morphogenetic Protein 9;
Pathologic Processes
- From:
Journal of Clinical Hepatology
2022;38(3):671-675
- CountryChina
- Language:Chinese
-
Abstract:
Portopulmonary hypertension (POPH) is an increase in pulmonary artery pressure that occurs on the basis of portal hypertension. As a member of the BMP family, bone morphogenetic protein 9 (BMP9) not only has the osteogenic activity, but can also protect endothelial integrity and maintain vascular homeostasis. This article reviews the pathogenesis of POPH, the physiological expression and role of BMP9, and related research advances in the BMP9 signaling pathway and its involvement in pulmonary hypertension and vascular remodeling, thereby exploring the possibility of BMP9 as a new biomarker for POPH to assist in the diagnosis of POPH.
